INDA: iShares MSCI India ETF returns, drawdowns and risk
Funds on emerging and Asian markets, as a block or country by country.
Data updated October 2026
INDA · US exchange · USDCategory: Emerging markets and Asia ETFsData from February 2012
From February 2012 to October 2026 INDA returned 5.0% a year on average with dividends reinvested, in US dollars: $10,000 invested at the start grew to $20,617.
Its deepest fall was 45.1%, from January 2018 to March 2020, and it took about 34 months to get back to the previous high. Annual volatility was 21.8%; at the last close it was 18.7% below its high.
Against SPY (SPDR S&P 500 ETF Trust), over the 176 months both have data, the correlation of monthly returns was 0.53: they moved together only in part. Beta was 0.70. In months when SPY rose, INDA moved 68% as much on average; in months when SPY fell, 93% as much.
Key figures
- Annual return (CAGR)
- +5.0%
- 1-year return
- −12.7%
- 5 years, a year
- +0.4%
- 10 years, a year
- +6.1%
- Annual volatility
- 21.8%
- Maximum drawdown
- −45.1%
- Sharpe ratio
- 0.26
- Worst year
- 2022: −8.9%
Trailing returns
| Period | INDA | SPY |
|---|---|---|
| 1 year | −12.7% | +16.6% |
| 3 years, a year | +3.0% | +23.1% |
| 5 years, a year | +0.4% | +12.7% |
| 10 years, a year | +6.1% | +15.4% |
To the last close of October 2026. Periods longer than a year are annualised.
Growth of $10,000: INDA vs SPY
Month-end values from March 2012, the first month both funds have data.
INDA drawdowns
Percentage below the previous high, weekly.
Returns by calendar year
| Year | INDA | SPY |
|---|---|---|
| 2026(partial) | −11.6% | +13.3% |
| 2025 | +2.7% | +17.7% |
| 2024 | +8.6% | +24.9% |
| 2023 | +17.2% | +26.2% |
| 2022 | −8.9% | −18.2% |
| 2021 | +21.3% | +28.7% |
| 2020 | +14.8% | +18.3% |
| 2019 | +6.5% | +31.2% |
| 2018 | −6.7% | −4.6% |
| 2017 | +36.1% | +21.7% |
| 2016 | −1.6% | +12.0% |
| 2015 | −7.1% | +1.2% |
| 2014 | +21.8% | +13.5% |
| 2013 | −5.2% | +32.3% |
| 2012(partial) | −1.4% | — |
INDA compared
How the figures are calculated
Total return in the fund’s trading currency, from end-of-day prices with dividends reinvested on the ex-date. The fund’s own ongoing charges are already reflected in its price; trading costs, taxes and currency conversion are not included. Past returns do not predict future returns.
Sharpe ratio uses the return of short-term government bills in the same currency as the risk-free rate. The growth chart uses month-end values; drawdowns and volatility use daily closes.
Questions
What is the average annual return of INDA?
From February 2012 to October 2026 INDA returned 5.0% a year on average (CAGR) with dividends reinvested, in USD. Over the last 5 years: +0.4% a year. Over the last 12 months: −12.7%.
What was the worst drawdown of INDA?
45.1%, from January 2018 to March 2020; it took about 34 months from the previous high to get back to it.
How volatile is INDA?
Annual volatility was 21.8% over the period. Its worst month was −25.1% and 58% of months were positive. Worst calendar year: 2022 (−8.9%).
How closely does INDA follow SPY?
Over 176 months the correlation of monthly returns was 0.53, so they moved together only in part, with a beta of 0.70.
Use INDA in a free tool
Other Emerging markets and Asia ETFs
- All Emerging markets and Asia ETFsReturns and risk side by side
- VWO — Vanguard FTSE Emerging Markets ETFCAGR +9.6%
- IEMG — iShares Core MSCI Emerging Markets ETFCAGR +6.0%
- EIMI — iShares Core MSCI Emerging Markets IMI UCITS ETF (Acc)CAGR +7.3%
- EEM — iShares MSCI Emerging Markets ETFCAGR +5.2%
- VFEM — Vanguard FTSE Emerging Markets UCITS ETF (Dist)CAGR +5.1%
- XMME — Xtrackers MSCI Emerging Markets UCITS ETF 1CCAGR +6.2%
- MCHI — iShares MSCI China ETFCAGR +2.6%
- FXI — iShares China Large-Cap ETFCAGR +3.0%
- KWEB — KraneShares CSI China Internet ETFCAGR +1.3%
- EWT — iShares MSCI Taiwan ETFCAGR +13.4%
- EWY — iShares MSCI South Korea ETFCAGR +7.8%
Source: MarketStack end-of-day prices, total return with dividends reinvested. Figures are historical and descriptive; they are not forecasts and not investment advice. MEDGE Capital does not recommend buying or selling any instrument. Risk disclaimer.